Dr David G. Shand
#117,253
Most Influential Person Now
Dr David G. Shand's AcademicInfluence.com Rankings
Dr David G. Shandmedical Degrees
Medical
#1703
World Rank
#2070
Historical Rank
Gastroenterology
#25
World Rank
#27
Historical Rank
Pharmacology
#155
World Rank
#192
Historical Rank
Dr David G. Shandphilosophy Degrees
Philosophy
#5149
World Rank
#7879
Historical Rank
Logic
#2474
World Rank
#3472
Historical Rank
Download Badge
Medical Philosophy
Dr David G. Shand's Degrees
- PhD Pharmacology University of California, San Francisco
- Doctorate Medicine University of California, San Francisco
Why Is Dr David G. Shand Influential?
(Suggest an Edit or Addition)Dr David G. Shand's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A physiological approach to hepatic drug clearance (1975) (1860)
- Effects of caffeine on plasma renin activity, catecholamines and blood pressure. (1978) (781)
- Reduced β‐adrenoceptor sensitivity in the elderly (1979) (563)
- Plasma propranolol levels in adults With observations in four children (1970) (562)
- Comparative Assessment of Stimuli That Release Neuronal and Adrenomedullary Catecholamines in Man (1979) (481)
- Plasma Propranolol Levels in the Quantitative Assessment of β-adrenergic Blockade in Man (1970) (324)
- Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. (1977) (311)
- Commentary: a physiological approach to hepatic drug clearance. (1975) (279)
- Clinical Pharmacology of Propranolol (1975) (261)
- A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol. (1972) (235)
- The Disposition of Propranolol (1972) (210)
- Altered Hepatic Blood Flow and Drug Disposition (1976) (206)
- Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension. (1976) (194)
- Effects of age and cigarette smoking on propranolol disposition (1979) (190)
- The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. (1973) (183)
- Clinical Pharmacokinetics of Propranolol (1979) (176)
- Disposition of propranolol V. Drug accumulation and steady‐state concentrations during chronic oral administration in man (1973) (174)
- Lidocaine plasma protein binding (1980) (174)
- Biological determinants of propranolol disposition in man (1978) (166)
- Prostaglandins and renin release: II. Assessment of renin secretion following infusion of PGI2,E2 and D2 into the renal artery of anesthetized dogs. (1978) (153)
- Direct measurement of propranolol bioavailability during accumulation to steady-state. (1978) (145)
- Suppression of Chronic Ventricular Arrhythmias with Propranolol (1979) (141)
- Pharmacokinetic and pharmacodynamic effects of diltiazem. (1983) (140)
- Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. (1974) (140)
- Plasma binding and the affinity of propranolol for a beta receptor in man (1976) (137)
- Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. (2005) (130)
- Disposition of propranolol VI. Independent variation in steady‐state circulating drug concentrations and half‐life as a result of plasma drug binding in man (1973) (127)
- Reduced verapamil clearance during long‐term oral administration (1981) (126)
- Plasma Propranolol Levels Associated with Suppression of Ventricular Ectopic Beats (1971) (126)
- Spuriously low plasma propranolol concentrations resulting from blood collection methods (1975) (125)
- Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat. (1979) (125)
- Effect of indomethacin and aspirin on gastric blood flow and acid secretion. (1977) (122)
- Regional hemodynamic effects of beta-adrenergic blockade with propranolol in the unanesthetized primate. (1973) (117)
- Reduced beta-adrenoceptor sensitivity in the elderly. (1979) (116)
- Time required for complete recovery from chronic propranolol therapy. (1973) (115)
- Effects of route of administration and blood flow on hepatic drug elimination. (1975) (115)
- Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. (1980) (113)
- The reduction of lidocaine clearance by dl-propranolol: an example of hemodynamic drug interaction. (1973) (112)
- Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling (1979) (111)
- Effect of route of administration on the relationship between β‐adrenergic blockade and plasma propranolol level (1972) (110)
- Propranolol Disposition in Chronic Liver Disease: A Physiological Approach (1976) (105)
- The disposition of propranolol. I. Elimination during oral absorption in man. (1972) (99)
- Sex-related differences in the plasma protein binding of lignocaine and diazepam. (1981) (94)
- Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. (1984) (93)
- The Influence of Cirrhosis on Steady-State Blood Concentrations of Unbound Propranolol after Oral Administration (1978) (92)
- Presystemic drug elimination. (1979) (87)
- Editorial: Propranolol Withdrawal Syndrome Why? (1978) (86)
- The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol. (1973) (84)
- Plasma concentrations and the time‐course of beta blockade due to propranolol (1975) (84)
- Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health. (1985) (75)
- Relationship between α1‐acid glycoprotein and lidocaine disposition in myocardial infarction (1981) (73)
- Reduction of Plasma Renin Activity by Inhibition of the Fatty Acid Cyclooxygenase in Human Subjects: Independence of Sodium Retention (1979) (72)
- Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats. (1982) (70)
- Individualization of propranolol therapy. (1974) (69)
- Inhibition of propranolol metabolism by chlorpromazine (1979) (63)
- Perfusion-limited effects of plasma drug binding on hepatic drug extraction (1976) (62)
- Pirmenol, A New Antiarrhythmic Agent: Initial Study of Efficacy, Safety and Pharmacokinetics (1982) (61)
- Diazepam and lidocaine plasma protein binding in renal disease (1982) (61)
- The ability of vascular tissue to produce prostacyclin decreases with age. (1981) (59)
- The artifactual nature of heparin‐induced drug protein‐binding alterations (1981) (54)
- Comparison of intravenous and oral verapamil dosing (1982) (54)
- The almost complete hepatic extraction of propranolol during intravenous administration in the dog. (1971) (54)
- The disposition of propranolol. IV. A dominant role for tissue uptake in the dose-dependent extraction of propranolol by the perfused rat liver. (1973) (54)
- Propranolol disposition in renal failure. (1980) (54)
- Differentiation of hemodynamic, humoral and metabolic responses to beta 1- and beta 2-adrenergic stimulation in man using atenolol and propranolol. (1983) (54)
- Metabolism of propranolol by rat liver microsomes and its inhibition by phenothiazine and tricyclic antidepressant drugs. (1971) (53)
- Effect of PGI2, PGE2 and 6-keto PGF1α on canine gastric blood flow and acid secretion (1978) (52)
- High-performance liquid chromatographic analysis of diltiazem and its metabolite in plasma. (1983) (51)
- Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia. (1983) (51)
- Pharmacokinetics of antiarrhythmic drugs. (1978) (50)
- Alterations in the Responses of the Sympathetic Nervous System and Renin in Borderline Hypertension (1979) (50)
- Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen. (1982) (49)
- Active uptake of propranolol by isolated rabbit alveolar macrophages and its inhibition by other basic amines. (1980) (47)
- Propranolol Binding in Plasma during Cardiopulmonary Bypass (1979) (45)
- Further Observations on Relationships between Antipyrine Half-life, Clearance and Volume of Distribution: An Appraisal of Alternative Kinetic Parameters Used to Assess the Elimination of Antipyrine (1980) (45)
- In support of cardiac chronotropic beta 2 adrenoceptors. (1986) (43)
- Hypertrophic obstructive cardiomyopathy in an infant--propranolol therapy for three years. (1971) (43)
- Prostaglandin and histamine involvement in the gastric vasodilator action of pentagastrin. (1977) (42)
- On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction. (1982) (42)
- The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver. (1973) (41)
- A comparison of the pulmonary, renal and hepatic extractions of PGI2 and PGE2 - PGI2 a potential circulating hormone. (1978) (40)
- Lignocaine disposition in blood in epilepsy. (1981) (40)
- Importance of blood-collection tubes in plasma lidocaine determinations. (1979) (40)
- The effects of age and smoking on the plasma protein binding of lignocaine and diazepam. (1985) (40)
- Relation between residual urine volume and response to treatment of urinary infection. (1970) (40)
- Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs. (1974) (39)
- α1-Acid Glycoprotein and Plasma Lidocaine Binding (1984) (39)
- Impaired drug metabolism in experimental cirrhosis in the rat. (1978) (38)
- The disposition of propranolol. VII. The effects of saturable hepatic tissue uptake on drug clearance by the perfused rat liver. (1973) (37)
- Hemodynamic and metabolic responses to exercise after adrenoceptor blockade in humans. (1984) (36)
- Estimation of residual urine volume with 131 I-hippuran. (1968) (35)
- Hypertensive response to propranolol in a patient treated with methyldopa—a proposed mechanism (1973) (34)
- Uptake of propranolol by the lung and its displacement by other drugs: involvement of the alveolar macrophage. (1980) (31)
- Influence of cimetidine on verapamil kinetics and dynamics (1984) (31)
- Biological determinants of altered pharmacokinetics in the elderly. (1982) (30)
- Drug therapy: Propranolol. (1975) (30)
- Pharmacokinetics of propranolol: a review. (1976) (29)
- Interaction of topical and oral timolol in glaucoma. (1979) (28)
- Clinical comparison of rapid infusion and multiple injection methods for lidocaine loading. (1981) (27)
- Increase in hepatic blood flow and d-propranolol clearance by glucagon in the monkey. (1973) (27)
- A radioreceptor assay for propranolol (1979) (25)
- Disposition of propoxyphene and propranolol in children (1976) (24)
- THE SELECTIVITY OF DRUGS BLOCKING GANGLIONIC TRANSMISSION IN THE RAT. (1964) (24)
- Adrenergic control of tendon jerk reflexes in man (1973) (24)
- Increased plasma propranolol binding in myocardial infarction. (1980) (24)
- High-performance liquid chromatography analysis of a new antiarrhythmic drug, pirmenol, in biological fluids (1981) (24)
- Control of lidocaine therapy: new perspectives. (1982) (24)
- Hepatic circulation and drug disposition in cirrhosis. (1979) (22)
- Rapid high-performance liquid chromatographic method for the measurement of atenolol in plasma using UV detection. (1983) (22)
- A loading‐maintenance regimen for more rapid initiation of the effect of guanethidine (1975) (22)
- Hemodynamic effects of the antiarrhythmic drug pirmenol (1982) (21)
- Pharmacokinetic Drug Interactions (1975) (21)
- Efficacy, safety, and pharmacokinetics of a concentration-maintaining regimen of intravenous pirmenol. (1983) (20)
- Comparison of high-dose and medium-dose propranolol in the relief of exercise-induced myocardial ischemia. (1983) (19)
- Hemodynamic drug interactions: the reduction of oxyphenbutazone clearance by dl-propranol in the dog. (1973) (19)
- The disposition of propranolol. II. Hepatic elimination in the rat. (1972) (18)
- The release of guanethidine and bethanidine by splenic nerve stimulation: a quantitative evaluation showing dissociation from adrenergic blockade. (1973) (17)
- Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings]. (1977) (17)
- Evidence for cardiac beta 2-adrenoceptors in man. (1983) (16)
- Drug disposition in liver disease. (1977) (16)
- EFFECTS OF CAFFEINE ON PLASMA RENIN ACTIVITY, CATECHOLAMINES AND BLOOD PRESSURE (1978) (16)
- The Clinical Pharmacology of Antihypertensive Drugs (1977) (15)
- Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction. (1981) (15)
- Verapamil plasma binding: relationship to alpha 1-acid glycoprotein and drug efficacy. (1983) (15)
- Beta 1-selective and non-selective beta-adrenoceptor blockade, anaerobic threshold and respiratory gas exchange during exercise. (1985) (15)
- Actions of gallamine and tetraethylammonium at the frog neuromuscular junction. (1966) (14)
- A free lignocaine index as a guide to unbound drug concentration. (1985) (14)
- Pharmacokinetic Properties of the β-Adrenergic Receptor Blocking Drugs (2012) (14)
- Heparin administration increases plasma warfarin binding in man. (1979) (13)
- Human safety profile of tolrestat: An aldose reductase inhibitor (1987) (12)
- A Re-evaluation of Intersubject Variation in Enzyme Induction in Man (1979) (12)
- Hemodynamic and metabolic responses to exercise after alpha 1-, beta 1-, and nonselective beta-adrenoceptor blockade in man. (1984) (11)
- alpha 1-Acid glycoprotein and plasma lidocaine binding. (1984) (11)
- Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. (1977) (10)
- PLASMA CONCENTRATIONS AND THE TIME-COURSE OF BETA BLOCKADE DUE TO PROPRANOLOL (1976) (10)
- Differentiation of Hemodynamic, Humoral and Metabolic Responses to β1‐ and β2‐adrenergic Stimulation in Man Using Atenolol and Propranolol (1983) (10)
- Saliva Concentrations of Lidocaine and Its Metabolites in Man (1982) (10)
- Antenolol: A Long-Acting Beta1-Adrenoceptor Antagonist (1982) (10)
- THE MODE OF ACTION OF DRUGS BLOCKING GANGLIONIC TRANSMISSION IN THE RAT. (1965) (10)
- Drug metabolism in rats bearing a pituitary mammotropic tumor. (1979) (9)
- Dose proportionality comparison of beta1 blocking activity of cetamolol hydrochloride and atenolol in normal subjects (1984) (9)
- Perfusion-limited of plasma drug binding on hepatic drug extraction. (1976) (8)
- Hemodynamic drug interactions. (1974) (8)
- Effects of Concentration and Steric Configuration of Propranolol on AV Conduction and Ventricular Repolarization in the Dog (1981) (8)
- The fate of SU‐13197, a new antiarrhythmic drug, in rat and man (1971) (8)
- Lidocaine and Its Metabolites in Canine Plasma and Myocardium (1983) (8)
- The mechanism of the reversal of the effect of guanethidine by amphetamines in cat and man. (1970) (7)
- Propranolol decreases serum thyroxine as well as triiodothyronine in rats: a protein-binding effect. (1983) (6)
- High-performance liquid chromatographic analysis of sulfinpyrazone and its metabolites in biological fluids. (1980) (6)
- Opening Remarks by Prof. M. Bergener, Köln (1982) (6)
- Regional hemodynamic effects of dopamine in the unanesthetized primate: failure to alter flow-dependent hepatic drug clearance. (1973) (5)
- Determinants ofplasmaa,-acid glycoprotein (AAG) concentrations inhealth (1985) (5)
- Editorial: Propranolol withdrawal. (1975) (5)
- Effect of Verapamil on Left Ventricular Function at Rest and During Exercise in Normal Men (1983) (5)
- Presystemic drug metabolism in the liver (1982) (4)
- Effect of Cetamolol on Epinephrine‐Induced Hypokalemia (1988) (4)
- Determinants of plasma a ,-acid glycoprotein ( AAG ) concentrations in health (2006) (4)
- Presystemic hepatic drug elimination in cirrhosis (1982) (3)
- Clinical pharmacology of the beta-blocking drugs: implications for the postinfarction patient. (1983) (3)
- Evidence that guanethidine does not block adrenergic nerves by acting as a false transmitter. (1970) (3)
- How should the proper dose of a beta blocker be determined? (1983) (3)
- A method for studying spinal pharmacology in man. (1970) (3)
- Proceedings: Presystemic hepatic elimination. (1974) (2)
- Beta-adrenergic blocking drugs after acute myocardial infarction. (1982) (2)
- Atenolol: a long-acting beta 1- adrenoceptor antagonist. (1982) (2)
- Drug/Drug Interactions and the Delivery of Drugs to their Site of Action—Important Clinical Aspects (1972) (2)
- Proceedings: High-affinity hepatic microsomal binding of propranolol: its relationship to metabolism and to the first-pass effect. (1974) (2)
- Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction. (1989) (2)
- Is it safe to use intravenous verapamil to treat a patient who is taking oral verapamil? (1983) (2)
- 2301 – AGE RELATED EFFECTS OF SMOKING ON ELIMINATION OF PROPRANOLOL (P) ANTIPYRINE (Ap) AND INDOCYANINE GREEN (ICG) (1978) (2)
- TIMOLOL MALEATE—A PROMISING NEW BETA ADRENERGIC BLOCKER FOR GLAUCOMA (1979) (1)
- Proceedings: The influence of glucagon on regional blood flow in the rhesus monkey. (1973) (1)
- DISCUSSION PAPER: RESULTS WITH PROPANOLOL (1973) (1)
- State-of-the-Art: Comparative Pharmacology of the β-Adrenoceptor Blocking Drugs (1983) (1)
- The effects of moderate and high dose propranolol on ventricular function in patients with coronary artery disease (1981) (1)
- Antiarrhythmic effects of the quaternary propranolol analog that does not induce beta‐adrenergic blockade (1982) (1)
- 2687 – REDUCED β-ADRENOCEPTOR SENSITIVITY IN THE ELDERLY (1978) (1)
- The Action of Propranolol in Man and Animals (1976) (0)
- from arrhythmia, are otherwise healthy. (1982) (0)
- DIRECTMEASUREMENTOF PROPRANOLOLBIOAVAILABILITY DURINGACCUMULATIONTO STEADY-STATE (1978) (0)
- 2897 – THE INFLUENCE OF CIRRHOSIS ON FREE PROPRANOLOL CONCENTRATION DURING CHRONIC ORAL ADMINISTRATION (1978) (0)
- Clinical comparison of raipid infusion and mwltipk injection meth& for lidocaine loading (1981) (0)
- REGISTER RERUM ad Vol. 43 (1960) (0)
- 340 – PHARMACOKINETICS OF THE FIRST PASS EFFECT (1977) (0)
- CLINICAL PHARMACOLOGY OF PROPRANOLOL animals (2005) (0)
- Radio-resistance of frog skeletal muscle alkaline phosphatases determined histochemically. (1960) (0)
- Propranolol in the treatment of cardiovascular disease. (1978) (0)
- 804 – BIOCHEMICAL CORRELATES OF ANTIHYPERTENSIVE DRUG RESPONSIVENESS (1978) (0)
- PHARMACOKINETICS OF THE FIRST PASS EFFECT (1976) (0)
- ON THE ROLE OF aI -ACID GLYCOPROTEIN IN LIGNOCAINE ACCUMULATION FOLLOWING MYOCARDIAL INFARCTION (2006) (0)
- The present status of propranolol. (1979) (0)
- Indomethacin, pentagastrin and gastric arterial blood flow (1976) (0)
- Contents, Vol. 43, 1960 (1960) (0)
- Bibby 2005 - Pk of dox-NPs - IntJPharm 293, 281 (2012) (0)
- 2114 – HYPERTONIC SALINE DECREASES RENAL BLOOD FLOW AND RENIN SECRETION “IN VIVO” (1978) (0)
- Drug-protein binding: discussion paper: results with propanolol. (1973) (0)
- Title Page / Table of Contents, Vol. 28, Supplement 1, 1982 (1982) (0)
- Subject Index Vol. 8, 1972 (1972) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Dr David G. Shand?
Dr David G. Shand is affiliated with the following schools:
